The activities of antituberculosis agents were evaluated in a murine tuberculosis model using a drug-resistant isolate. A multidrug-resistant clinical isolate from a recent outbreak of tuberculosis in the New York State correctional system was used for infection. Approximately 107 viable Mycobacterium tuberculosis ATCC 49967 (strain CNL) organisms were given intravenously to 4-week-old female outbred mice. Treatment was started 1 day after infection and given for 4 weeks. Spleens and lungs were homogenized, and viable cell counts were determined. Statistical analysis indicated that ethionamide, sparfloxacin, ofloxacin, capreomycin, clarithromycin, and clofazimine are active in the murine test system with this multidrug-resistant tuberculosis isolate.
Since 1985, a resurgence of tuberculosis has occurred in the United States, due in part to the human immunodeficiency virus pandemic (2, 6, 14) . Institutional and community-based outbreaks of multidrug-resistant tuberculosis (MDR-TB) have occurred with high mortality rates in immunocompromised individuals (3, 13, 26) .
During the period from August to October 1991, an outbreak of MDR-TB among inmates in New York State correctional facilities resulted in nosocomial transmission to inpatients and health care workers at SUNY Health Science Center in Syracuse, N.Y. (5) . Seventy-four health care workers converted their tuberculin skin tests; one inpatient hospitalized during the outbreak and two health care workers subsequently developed active pulmonary MDR-TB (5, 9) . Management of individuals with active MDR-TB has been difficult, and appropriate preventive chemotherapy for health care workers who converted their skin test remains undefined (4, 12) .
The purpose of the present study was to evaluate the comparative activities of currently available agents and agents in preclinical development in a murine model of multidrug-resistant tuberculosis, using the outbreak isolate. (20) to make pairwise comparisons among means. The results of the statistical evaluations are summarized in the following section.
RESULTS
Infection study 1 ( Fig. 1 and Table 2 ). TEM, SPA, or CAP (150 mg/kg of body weight), OFL or CS (300 mg/kg), or ETA (125 mg/kg) was given 5 days per week for 4 weeks to female mice which had been infected with 1.6 x 107 viable M. tuberculosis organisms. Treatment with TEM, SPA, CAP, OFL, or ETA reduced cell counts in spleens and lungs compared with those in mice given no treatment (P < 0.01). Of the quinolones, SPA was more active than TEM or OFL (21) . Enhanced activity might be expected if a higher INH dose were given on an intermittent basis (75 mg/kg three times per week); however, there was only a modest difference between numbers of organisms in the lungs of mice treated with the higher and lower INH doses.
PZA was inactive against this isolate, as predicted by the results of our in vitro susceptibility testing. Discordant MIC results have been reported for this isolate by other laboratories (5); however, susceptibility testing for PZA is technically difficult (15, 16) .
Of current second-line antituberculous agents, CAP had modest activity and CS had no activity in the murine test system. The relative activity of CS may be underestimated because of the high rate of CS excretion in the mouse (8, 25) . Perhaps two-or three-times-per-day dosing of CS would better approximate the human pharmacokinetics of this agent. ETA had moderate activity against the drug-resistant isolate, although this agent is often poorly tolerated in humans because of dose-related gastrointestinal side effects (10) . ETA administered at a lower dose in the murine test system had limited activity.
Newer quinolones were active in the murine test system of drug-resistant tuberculosis. SPA was the most active quinolone tested. The area under the concentration-time curve for mice dosed with SPA at 100 mg/kg approximates that for humans following a single 400-mg oral dose (23, 24) . SPA was more active than OFL, a finding obtained by Ji et al. with a murine tuberculosis model using a drug-susceptible isolate (19) .
CLA had modest activity in the murine test system; however, it was relatively less active against organisms in the lungs than against organisms in the spleens. This same trend has been noted for CLA activity against Mycobacterium avium complex in the beige mouse (22) . CLA was subsequently evaluated against a drug-susceptible isolate of M. tuberculosis in a similar murine system (21) . There was little activity against organisms in spleens or lungs; therefore, this agent should probably not be used for the treatment of tuberculosis.
As reflected in the in vitro susceptibility results, there was complete cross-resistance between RIF and the newer rifamycins against this isolate in vivo, perhaps due to the high level of rifamycin resistance. It may be useful to assess in vivo activity of the newer rifamycins against M. tuberculosis isolates with lower levels of in vitro resistance. Improved understanding of the correlation between in vitro and in vivo rifamycin activity will help to clarify the potential role of RBT or RPT in the treatment of RIF-resistant tuberculosis (7, 11, 17) .
CFZ was active in the murine test system, although its place in the treatment of tuberculosis is not clear. CFZ has promising in vitro activity against M. tuberculosis, with MICs in the range of 0.1 to 10 ,g/ml, depending on the pH of the media (1) . This agent has activity in mouse and guinea pig models of tuberculosis, but not in a rhesus monkey model of infection (27) . Assessment of activity in human clinical disease is necessary to judge the role of CFZ as an antituberculosis agent.
The organism used in this study was found to be resistant to INH and ETA and susceptible to PZA by other investigators (4). It is likely that quantitative susceptibility testing of "resistant" isolates would provide information useful in designing treatment regimens for individuals infected with these organisms. Individuals may benefit from therapy with INH and ETA when isolates with low-level resistance occur. Individuals would derive little if any benefit from therapy with rifamycins when isolates with high-level resistance occur.
Management of drug-resistant tuberculosis, particularly in individuals with human immunodeficiency virus infection, is difficult and associated with a high risk of treatment failure (4, 18) . There has been limited study of drug-resistant tuberculosis in animal systems. Quantitative susceptibility testing coupled with in vivo study of multidrug-resistant isolates in murine test systems will improve our understanding of the relationship between these parameters of antimicrobial activity. The lesson from this initial study is that our current breakpoint susceptibility testing method is satisfactory in predicting susceptible isolates but provides inadequate information with regard to "resistant" isolates. Further evaluation of the use of antimycobacterial agents against drug-resistant isolates will provide data that will be useful for the design of clinical trials and/or algorithms for treatment of infection with these organisms. The most effective approach to understanding the biology of drug-resistant tuberculosis is the study of these organisms both in vitro and in vivo.
